Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,075,000 shares of Scienture Holdings, Inc. common stock, representing 5.55% of the outstanding class based on 19,356,180 shares cited in the issuer's prospectus supplement. The filing states the fund has sole voting and sole dispositive power over these shares and includes a standard disclaimer noting two directors of the fund, David Feldman and Joel Arber, may be deemed to have an interest but disclaim beneficial ownership except to the extent of pecuniary interest.
Scienture Holdings, Inc. entered into a registered direct stock offering with institutional investors, selling 3,225,000 common shares at $1.20 per share for gross proceeds of approximately $3.87 million. The sale was made under an effective shelf registration statement on Form S-3 and closed on August 15, 2025. Maxim Group LLC acted as exclusive placement agent and will receive a cash fee equal to 7.0% of the gross proceeds plus up to $50,000 of expense reimbursement. The company agreed not to issue additional equity or file most new registration statements for 15 days after closing, while officers and directors are subject to 90-day lock-ups. Separately, between July 18 and August 11, 2025, Scienture raised about $1.76 million in a private sale of 1,110,060 shares, with proceeds used for working capital, capital spending, product development, and other corporate purposes.
Prospectus supplement summary: The document presents terms of a securities offering and related company disclosures. The placement agent fee is stated as $0.08 per share totaling $270,900, and the proceeds before expenses are shown as $1.12 per share totaling $3,599,100. The filing lists common shares outstanding at various points: 126,683,845, 127,894,248, and 130,828,731. A historical net tangible book value per share is disclosed as $(1.27). The company notes anticipated capitalization changes from the conversion of secured convertible promissory notes, conversion of Series B preferred stock, and potential exercise of 2,270,672 options (weighted average exercise price $1.22) and 238,594 warrants (weighted average exercise price $19.02). The filing also states that Scienture, LLC relies on third‑party CMOs for all manufacturing and does not own manufacturing facilities.
Scienture Holdings, Inc. (f/k/a TRxADE Health) reported a weak operating quarter with minimal revenue and mounting losses while consolidating a major acquisition. Total assets were $104.3 million, driven primarily by $76.4 million of acquired product technology intangibles and $21.37 million of goodwill from the July 25, 2024 Scienture acquisition. One product, SCN-102, received regulatory approval in March 2025 and commercialization is projected to begin in 2025.
Operating results show revenues of $10,258 for the six months ended June 30, 2025 and a net loss from continuing operations of $9.78 million for the same period (quarter loss $6.72 million). Cash on hand was $15,391 at June 30, 2025 and the company discloses substantial doubt about its ability to continue as a going concern. The company completed divestitures of legacy subsidiaries for a $5.0 million promissory note and maintains convertible debentures and a derivative liability related to a $3.33 million Arena financing.
Scienture Holdings, Inc. (f/k/a TRxADE Health) filed an amended Form D to update its private placement details.
- Offering: Equity securities under Reg D Rule 506(b) & Securities Act §4(a)(5).
- Size: $3.0 million; $1.715 million (≈57%) sold since first sale on 18 Jul 2025; $1.285 million remains.
- Investors: 8 participants; minimum investment $50,000.
- Compensation: Finalis Securities LLC to receive $35,000 sales commission; no finder’s fees.
- Use of proceeds: General working capital; no payments to executives/directors.
- Issuer profile: Delaware corporation, principal office Commack, NY; operates in Pharmaceuticals; revenue range not disclosed; offering expected to close within one year.
The amendment confirms meaningful investor traction and continued capital needs as the company works toward its $3 million goal.